Troubled Ventracor Of Australia Answers Critics Over Heart Pumps
This article was originally published in PharmAsia News
Australia's Ventracor denied accusations to the contrary and said it complied fully with federal rules in three instances in which patients died after being implanted with its heart pumps. The company has been accused of delaying notices to investors about problems, which led to an ordered halt to trading in its stock. Ventracor says the three deaths were reported to health authorities and it was not required to disclose them to the stock market. It also said the fractures in its pumps in the three cases were caused by "accidental trauma" and that in eight other non-fatal incidents, the implanted patients were not wearing their support belts. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.